Supplemental Tables

Table 1: Patient and aneurysm characteristics for unruptured and ruptured aneurysms

Characteristics	Unruptured aneurysms						Ruptured aneurysms			
Patient age	55 ± 12 years (27 -79 years)						55 ± 10 years (36 -71 years)			
Aneurysm location	ICA	BA	MCA	VA	ACOM	Other	ICA	BA	VA	Other
	109 (76.2%)	9 (6.3%)	9 (6.3%)	6 (4.2%)	6 (4.2%)	4 (2.8%)	8 (44.4%)	4 (22.2%)	3 (16.7%)	3 (16.7%)
Aneurysm size[1] [mm]	8.4 ± 6.4 (2.0 – 46.0)						3.3 ± 2.0 (1.0 – 8.0)			
Neck diameter [mm]	4.9 ± 3.9 (1.0 – 36.0)						2.8 ± 1.9 (1.0 – 6.2)			
Dome-to-neck ratio	1.7 ± 0.8 (0.4 – 5.1)						1.6 ± 1.6 (0.9 – 7.5)			
Diameter of the parent artery proximal and distal to the aneurysm [mm]	Proximal			Distal			Proximal		Distal	
	3.6 ± 0.8 (1.5 – 7.0)			3.1 ± 0.7 (1.3 – 5.2)			3.0 ± 0.7 (1.9 – 4.3)		2.5 ± 0.8 (1.2 – 4.0)	
Aneurysm type	Saccular	Fusiform		Blister-like	Dissecting		Blister-like	Saccular	Dissecting	Fusiform
	126 (88.1%)	10 (7.0%)		5 (3.5%)	2 (1.4%)		9 (50.0%)	5 (27.8%)	3 (16.7%)	1 (5.6%)
Sidewall or bifurcation aneurysm	Sidewall			Bifurcation			Sidewall		Bifurcation	
	122 (85.3%)			21 (14.7%)			14 (77.8%)		4 (22.2%)	

Data indicated as Mean ± standard deviation (minimum – maximum) or absolute number of cases (relative frequency in %). ICA: internal carotid artery; BA: basilar artery; PCOM: posterior communicating artery; MCA: middle cerebral artery; VA: vertebral artery; [1]maximal diameter

Table 2: Treatment parameters, complications and occlusion rates

Treatment parameters	**Unruptured aneurysms**					**Ruptured aneurysms**				
Aneurysms treated in the respective treatment session	One 128 (89.5%)	Two 11 (77.7%)	Three 2 (1.4%)	Four 2 (1.4%)		One 16 (88.9%)	Two 2 (11.1%)			
Additional coiling	45 (31.5%)					3 (16.7%)				
In-stent PTA	4 (2.8%)					0 (0%)				
Adverse events and complications										
Adverse event	Technical periprocedural adverse event 5 (3.5%)	Minor adverse event 17 (11.9%)	Major adverse event 4 (2.8%)	Neurological morbidity 2 (1.4%)	Mortality 1 (0.7%)	Technical periprocedural adverse event 0 (0%)	Minor adverse event 4 (22.2%)	Major adverse event 1 (5.6%)	Neurological morbidity 1 (5.6%)	Mortality 1 (5.6%)
Occlusion rates										
Occlusion at latest follow-up[7]	I: Complete occlusion 88 (68.2%)		II: Residual neck 21 (16.3%)	III: Residual aneurysm 20 (15.5%)		I: Complete occlusion 6 (46.2%)		II: Residual neck 3 (23.1%)	III: Residual aneurysm 4 (30.8%)	

Data indicated as absolute number of cases (relative frequency in %). [1]Imaging follow-up was available for 142/161 patients with a mean follow-up period: 7.0 months, reported according to the Raymond-Roy classification.

Supplemental Table 3: Adverse events and complications (unruptured and ruptured aneurysms)

Adverse event	No. of observed events	Intra-procedural	Post-procedural	Minor adverse event[1]	Major adverse event[2]	Neurological complication	Neurological morbidity	Mortality
Asymptomatic adverse event								
Fishmouthing	8 (5.0%)	0 (0%)	8 (5.0%)	-	-	-	-	-
Stent thrombosis	5 (3.1%)	4 (2.5%)	1 0.6%	-	-	-	-	-
Insufficient opening	1 (0.6%)	1 (0.6%)	0 (0%)	-	-	-	-	-
Stent shortening	2 (0.6%)	2 (1.2%)	0 (0%)	-	-	-	-	-
Kinking of device	1 (0.6%)	1 (0.6%)	0 (0%)	-	-	-	-	-
Coil migration	1 (0.6%)	1 (0.6%)	0 (0%)	-	-	-	-	-
Radial artery occlusion	1 (0.6%)	0 (0%)	1 (0.6%)	-	-	-	-	-
Summary	21 (13.0%)	9 (5.6%)	12 (7.5%)	-	-	-	-	-
Symptomatic adverse events								
Groin hematoma	5 (3.1%)	1 (0.6%)	4 (2.5%)	5 (3.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Visual disturbances	5 (3.1%)	0 (0%)	5 (3.1%)	5 (3.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ischemic stroke	4 (2.5%)	0 (0%)	4 (2.5%)	2 (1.2%)	2 (1.2%)	4 (2.5%)	2 (1.2%)	0 (0%)
Stent thrombosis	3 (1.9%)	0 (0%)	3 (1.9%)	1 (0.6%)	2 (1.9%)	3 (2.5%)	1 (0.6%)	0 (0%)
TIA	2 (1.9%)	0 (0%)	2 (1.9%)	2 (1.2%)	0 (0%)	2 (1.9%)	0 (0%)	0 (0%)
Vasospasm[3]	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	0 (0%)
CA-induced encephalopathy	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	0 (0%)	1 (0.6%)	0 (0%)	0 (0%)
Intracerebral hemorrhage	1 (0.6%)	0 (0%)	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	0 (0%)	1 (0.6%)
Seizure	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	0 (0%)	1 (0.6%)	0 (0%)	0 (0%)
Mass effect	1 (0.6%)	0 (0%)	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	0 (0%)	1 (0.6%)
Epistaxis	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CA allergy	1 (0.6%)	0 (0%)	1 (0.6%)	1 (0.6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Summary[4]	24 (14.9%)	1 (0.6%)	23 (14.3%)	21 (13.0%)	5 (3.1%)	12 (7.5%)	3 (1.9%)	2 (1.2%)

CA: contrast agent; [1]event which resolved within 7 days without any clinical sequelae; [2]ongoing clinical deficit at 7 days following the event; [3]related to subarachnoid hemorrhage; [4]for directly related adverse events (one case of intracerebral hemorrhage leading to a stop of the antiplatelet therapy, resulting in stent thrombosis and fatal major ischemic stroke and one case of stent thrombosis leading to major ischemic stroke, resulting in neurological morbidity) only the initiating event is counted in the summary